Seeking Alpha

Cowen goes against the grain on Celgene (CELG +2.3%) with an upgrade to "outperform" from...

Cowen goes against the grain on Celgene (CELG +2.3%) with an upgrade to "outperform" from "neutral," saying that the pharma play has high visibility and revenue predictability. Cowen also assumes an expanded EU label for Revlimid in 2015 despite last week's regulatory setback for the drug. Cowen's note comes after other firms cut their price targets on Celgene.
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs